Literature DB >> 33659574

Colorimetric RhoB GTPase Activity Assay.

Kossay Zaoui1,2, Stephanie Duhamel2.   

Abstract

The Ras homologous protein (Rho) GTPase subfamily, including RhoA, RhoB, and RhoC are small molecules (~21 kDa) that act as molecular switches in a wide range of signaling pathways to orchestrate biological processes associated with both physiological and tumorigenic cellular states. The Rho GTPases are crucial regulators of actin cytoskeleton rearrangements and FA dynamics and are required for effective cell migration and invasion, as well as cell cycle progression and apoptosis. The Rho GTPases activity is regulated by conformational switching between GTP-bound (active) and GDP-bound (inactive) states. This GTP/GDP cycling is tightly controlled by the guanine nucleotide exchange factors (GEFs), which function as activators by catalyzing the exchange of GDP for GTP and by the GTPase-activating proteins (GAPs), which enable hydrolysis of GTP leading to the Rho GTPase inactivation. Here, we describe a detailed protocol to perform a RhoB G-LISA activation assay to detect the level of GTP-loaded RhoB in vitro. This is the first colorimetric assay designed to specifically measure RhoB activation. This method was developed by adapting the RhoA G-LISA Activation Assay Kit (Cytoskeleton, Inc.) and allow the precise measurement of RhoB activity in less than 3 hours. This rapid methodology can be broadly used to assess the level of GTP-loaded RhoB in any kind of cellular models, to appreciate either the role RhoB activation in physiological processes, diseases, oncogenic transformation or for drug discovery in high throughput screens.
Copyright © 2020 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  GTP-loaded; GTP/GDP cycling; In vitro colorimetric G-LISA activation assay; Rho GTPases activity; RhoB

Year:  2020        PMID: 33659574      PMCID: PMC7842779          DOI: 10.21769/BioProtoc.3609

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  10 in total

Review 1.  Cell migration: integrating signals from front to back.

Authors:  Anne J Ridley; Martin A Schwartz; Keith Burridge; Richard A Firtel; Mark H Ginsberg; Gary Borisy; J Thomas Parsons; Alan Rick Horwitz
Journal:  Science       Date:  2003-12-05       Impact factor: 47.728

Review 2.  Dynamics of the Rho-family small GTPases in actin regulation and motility.

Authors:  Désirée Spiering; Louis Hodgson
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

Review 3.  Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility.

Authors:  Ann P Wheeler; Anne J Ridley
Journal:  Exp Cell Res       Date:  2004-11-15       Impact factor: 3.905

4.  Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities.

Authors:  De-An Wang; Said M Sebti
Journal:  J Biol Chem       Date:  2005-02-15       Impact factor: 5.157

5.  Loss of RhoB expression in human lung cancer progression.

Authors:  Julien Mazieres; Teresita Antonia; Ghislaine Daste; Carlos Muro-Cacho; Delphine Berchery; Vanessa Tillement; Anne Pradines; Said Sebti; Gilles Favre
Journal:  Clin Cancer Res       Date:  2004-04-15       Impact factor: 12.531

Review 6.  Rho GTPases in cancer: friend or foe?

Authors:  Julius H Svensmark; Cord Brakebusch
Journal:  Oncogene       Date:  2019-08-19       Impact factor: 9.867

Review 7.  The RhoB small GTPase in physiology and disease.

Authors:  Francisco M Vega; Anne J Ridley
Journal:  Small GTPases       Date:  2016-11-22

8.  Arf6 regulates RhoB subcellular localization to control cancer cell invasion.

Authors:  Kossay Zaoui; Charles V Rajadurai; Stéphanie Duhamel; Morag Park
Journal:  J Cell Biol       Date:  2019-10-07       Impact factor: 10.539

9.  The C-terminal sequence of RhoB directs protein degradation through an endo-lysosomal pathway.

Authors:  Dolores Pérez-Sala; Patricia Boya; Irene Ramos; Mónica Herrera; Konstantinos Stamatakis
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

Review 10.  RhoB: Team Oncogene or Team Tumor Suppressor?

Authors:  Julia A Ju; Daniele M Gilkes
Journal:  Genes (Basel)       Date:  2018-01-30       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.